When was H2-Pharma founded?

H2-Pharma was founded in 2013 and raised its 1st funding round 7 years after it was founded.

Where is H2-Pharma located?

H2-Pharma is headquartered in Montgomery, United States.

How many employees does H2-Pharma have?

As of Jul 01, 2024, the latest employee count at H2-Pharma is 5.

Is H2-Pharma a funded company?

H2-Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Oct 21, 2020.

When was the latest funding round of H2-Pharma?

H2-Pharma's latest funding was a $***** Seed round on Oct 21, 2020, with participation from 1 investor.

Where does H2-Pharma rank among its competitors?

H2-Pharma ranks 14th amongst 54 active competitors, of which 3 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Provell Pharmaceuticals, which secured $600K in Jan, 2024.

Who are the top competitors of H2-Pharma?

H2-Pharma's top competitors include Pfizer, Cost Plus Drug and Lovell Government Services. Among them, Provell Pharmaceuticals secured the most recent funding round in January, 2024.

H2-Pharma - 2026 Company Profile, Funding & Competitors

H2-Pharma is an acquired company based in Montgomery (United States), founded in 2013. It operates as a Pharmaceutical company focused on sales, marketing, and distribution of Rx and non-Rx products. H2-Pharma has raised an undisclosed amount in funding from Ardian. The company has 54 active competitors, including 3 funded and 10 that have exited. Its top competitors include companies like Pfizer, Cost Plus Drug and Lovell Government Services.

Company Details

Pharmaceutical company focused on sales, marketing, and distribution of Rx and non-Rx products. They specialize in navigating U.S. sales channels, providing safe and cost-efficient medications. They actively seek strategic partnerships for portfolio expansion through in-licensing and joint development projects. Their core strengths include experience, efficiency, competency, and adaptability, demonstrated by launching numerous products through global partnerships. They focus on branded and generic medications, aiming to meet high standards in the pharmaceutical supply chain. They are not a tech company, SaaS, Software, Cloud Based,cart, login, book now, subsciprtion, pricing, Blockchain, or Artifical Intellignece company.

Website: www.h2-pharma.com/
Email ID: *****@h2-pharma.com
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Montgomery, United States

Stage

Acquired

Latest Funding Round

Seed, Oct 21, 2020, $*****

Investors

Ardian

Ranked

14^th among 54 active competitors

Employee Count

5 as on Jul 01, 2024

Similar Companies

Pfizer & 441 more

Exit Details

Acquired by ANI Pharmaceuticals (Feb 01, 2016)

View H2-Pharma's full profile

H2-Pharma got acquired by ANI Pharmaceuticals on Feb 01, 2016 at an acquisition amount of $*****.

Click here to take a look at H2-Pharma's acquisition in detail

H2-Pharma has raised funding over 1 round. Its latest funding round was a Seed round on Oct 21, 2020 for $*****. 1 investor participated in its latest round. H2-Pharma has 1 institutional investor.

Here is the list of recent funding rounds of H2-Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 21, 2020	2208047	Seed	7624759	9650912	4407112	3752459

Access funding benchmarks and valuations. Sign up today!

View details of H2-Pharma's funding rounds and investors

H2-Pharma's employee count trend

H2-Pharma has 5 employees as of Jul 24. Here is H2-Pharma's employee count trend over the years:

Uncover H2-Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of H2-Pharma include Pfizer, Cost Plus Drug and Lovell Government Services. Here is the list of Top 10 competitors of H2-Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	79/100
2nd	Cost Plus Drug 2016, Dallas (United States), Unfunded	Distributor of generic drugs	-	-	43/100
3rd	Lovell Government Services 2013, Pensacola (United States), Unfunded	Distributor of pharmaceutical products	-	-	40/100
4th	Provell Pharmaceuticals 2005, Honey Brook (United States), Seed	Distributor of generic drugs	$9.6M	Flerie	35/100
5th	Aurobindo Pharma USA 1994, East Windsor (United States), Unfunded	Distributor of generic drugs	-	-	35/100
6th	KeySource 1996, Cincinnati (United States), Acquired	Distributor of pharmaceutical products	-	HEPCO Capital Management	32/100
7th	Auburn 1993, Rochester Hills (United States), Unfunded	Wholesaler distributes generic drugs purchased directly from manufacturers to pharmacies	-	-	28/100
8th	Bayshore Pharmaceuticals 2011, Short Hills (United States), Acquired	Manufacturer of pharmaceutical products	-	-	27/100
9th	Red Oak Sourcing 2014, Foxborough (United States), Seed	Distributor of generic drugs	$2.1M	-	26/100
10th	Peli BioThermal 2003, Maple Grove (United States), Unfunded	Provider of generic drugs distribution and packaging services	-	-	26/100
14th	H2-Pharma 2013, Montgomery (United States), Acquired	Pharmaceutical company focused on sales, marketing, and distribution of Rx and non-Rx products	-	Ardian	23/100